Cytosorbents Statistics

Total Valuation

Cytosorbents has a market cap or net worth of $37.62 million. The enterprise value is $61.23 million.

Market Cap	37.62M
Enterprise Value	61.23M

Important Dates

The next estimated earnings date is Wednesday, May 13, 2026, after market close.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Cytosorbents has 62.70 million shares outstanding. The number of shares has increased by 14.32% in one year.

Current Share Class	62.70M
Shares Outstanding	62.70M
Shares Change (YoY)	+14.32%
Shares Change (QoQ)	+0.08%
Owned by Insiders (%)	12.57%
Owned by Institutions (%)	26.76%
Float	54.82M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.04
Forward PS	0.94
PB Ratio	6.51
P/TBV Ratio	14.33
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1.65
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.13, with a Debt / Equity ratio of 4.93.

Current Ratio	2.13
Quick Ratio	1.42
Debt / Equity	4.93
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-5.45

Financial Efficiency

Return on equity (ROE) is -96.39% and return on invested capital (ROIC) is -24.38%.

Return on Equity (ROE)	-96.39%
Return on Assets (ROA)	-19.44%
Return on Invested Capital (ROIC)	-24.38%
Return on Capital Employed (ROCE)	-41.30%
Weighted Average Cost of Capital (WACC)	10.09%
Revenue Per Employee	$287,310
Profits Per Employee	-$63,550
Employee Count	129
Asset Turnover	0.81
Inventory Turnover	2.64

Taxes

Income Tax	-401,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -44.17% in the last 52 weeks. The beta is 1.48, so Cytosorbents's price volatility has been higher than the market average.

Beta (5Y)	1.48
52-Week Price Change	-44.17%
50-Day Moving Average	0.66
200-Day Moving Average	0.78
Relative Strength Index (RSI)	46.84
Average Volume (20 Days)	68,695

Short Selling Information

The latest short interest is 2.04 million, so 3.26% of the outstanding shares have been sold short.

Short Interest	2.04M
Short Previous Month	2.02M
Short % of Shares Out	3.26%
Short % of Float	3.73%
Short Ratio (days to cover)	18.05

Income Statement

In the last 12 months, Cytosorbents had revenue of $37.06 million and -$8.20 million in losses. Loss per share was -$0.13.

Revenue	37.06M
Gross Profit	26.49M
Operating Income	-14.24M
Pretax Income	-8.60M
Net Income	-8.20M
EBITDA	-12.74M
EBIT	-14.24M
Loss Per Share	-$0.13

Full Income Statement

Balance Sheet

The company has $6.25 million in cash and $29.11 million in debt, giving a net cash position of -$22.86 million or -$0.36 per share.

Cash & Cash Equivalents	6.25M
Total Debt	29.11M
Net Cash	-22.86M
Net Cash Per Share	-$0.36
Equity (Book Value)	5.90M
Book Value Per Share	0.09
Working Capital	10.93M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$12.38 million and capital expenditures -$164,000, giving a free cash flow of -$12.54 million.

Operating Cash Flow	-12.38M
Capital Expenditures	-164,000
Depreciation & Amortization	1.50M
Net Borrowing	2.48M
Free Cash Flow	-12.54M
FCF Per Share	-$0.20

Full Cash Flow Statement

Margins

Gross margin is 71.48%, with operating and profit margins of -38.42% and -22.12%.

Gross Margin	71.48%
Operating Margin	-38.42%
Pretax Margin	-23.20%
Profit Margin	-22.12%
EBITDA Margin	-34.38%
EBIT Margin	-38.42%
FCF Margin	n/a

Dividends & Yields

Cytosorbents does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.32%
Shareholder Yield	-14.32%
Earnings Yield	-21.36%
FCF Yield	-32.68%

Analyst Forecast

The average price target for Cytosorbents is $5.38, which is 796.67% higher than the current price. The consensus rating is "Buy".

Price Target	$5.38
Price Target Difference	796.67%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	42.98%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on December 5, 2014. It was a reverse split with a ratio of 1:25.

Last Split Date	Dec 5, 2014
Split Type	Reverse
Split Ratio	1:25

Scores

Cytosorbents has an Altman Z-Score of -8.92 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.92
Piotroski F-Score	2